The FDA has delivered a Commissioner's National Priority Voucher (CNPV) to Johnson & Johnson for a combination regimen based ...

The clinical trial industry is at a critical juncture where traditional methods are proving insufficient for managing today’s ...

Kyverna has previously reported positive midstage data with miv-cel in generalised myasthenia gravis (gMG), another ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Benedict Cross, Chief Technology Officer at PhoreMost, a ...

Tolebrutinib was one of three oral BTK inhibitors that Sanofi acquired as part of its $3.7 billion buyout of Principia ...

The latest judgment follows another setback in its defence in October, when a California jury awarded an eye-watering $966 ...

At the same time, the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) has progressed, and the UK has ...

Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is ...

Omnichannel didn’t fail pharma. Our metrics did. In 2026, fixing that won’t be optional. It will separate teams that keep ...

Sobi has hit the acquisition trail with a deal to buy Arthrosi Therapeutics for up to $1.5 billion, adding a drug in late-stage clinical testing for gout.

Today, the EU Council and Parliament reached an agreement in principle on the long-awaited pharma reform package, but ...

The UK government has confirmed that the rebate rate for newer medicines supplied to the NHS under the Voluntary Scheme for ...